儿童特应性皮炎管理临床指南
美国皮肤病学会(AAD)基于系统评价与GRADE方法制定儿童及青少年特应性皮炎(AD)的循证建议,共27条,涵盖外用治疗、光疗及系统治疗。强推荐包括保湿剂、外用钙调磷酸酶抑制剂、外用糖皮质激素、多种外用新药及生物制剂/JAK抑制剂等;条件推荐 bathing、漂白浴、湿包裹、光疗及部分免疫抑制剂;条件反对外用抗菌药与PUVA,强烈反对系统糖皮质激素。
要点
- 强推荐保湿剂、外用钙调磷酸酶抑制剂、外用糖皮质激素及多种靶向外用新药用于儿童AD。
- 强推荐dupilumab、tralokinumab、lebrikizumab、nemolizumab及JAK抑制剂等系统治疗。
- 强烈反对系统糖皮质激素;条件反对外用抗菌药与PUVA光疗。
核心结论
- 对儿童及青少年AD,强推荐保湿剂、外用钙调磷酸酶抑制剂、外用糖皮质激素、crisaborole软膏、roflumilast乳膏、ruxolitinib乳膏、tapinarof乳膏、dupilumab、tralokinumab、lebrikizumab、nemolizumab联合外用治疗、upadacitinib、abrocitinib及baricitinib。
- 条件推荐沐浴、漂白浴、湿包裹、光疗、甲氨蝶呤、吗替麦考酚酯、硫唑嘌呤及环孢素。
- 条件反对使用外用抗菌药与PUVA光疗,强烈反对使用系统糖皮质激素。
研究设计与样本
- 由多学科工作组进行系统评价,采用GRADE方法评估证据确定性并制定与分级推荐。
- 共形成27条关于儿童AD医疗管理的循证推荐。
主要发现
- 工作组基于系统评价形成27条循证推荐,涵盖外用治疗、光疗和系统治疗。
- 多数AD治疗随机对照试验持续时间短,限制了长期疗效与安全性结论。
关键数值与推荐
- 强推荐:保湿剂、外用钙调磷酸酶抑制剂、外用糖皮质激素、crisaborole软膏、roflumilast乳膏、ruxolitinib乳膏、tapinarof乳膏、dupilumab、tralokinumab、lebrikizumab、nemolizumab联合外用治疗、upadacitinib、abrocitinib、baricitinib。
- 条件推荐:沐浴、漂白浴、湿包裹、光疗、甲氨蝶呤、吗替麦考酚酯、硫唑嘌呤、环孢素。
- 条件反对:外用抗菌药、PUVA光疗;强烈反对:系统糖皮质激素。
临床怎么用
- 儿童AD应优先选用强推荐的外用治疗(保湿剂、TCS、TCI及新型外用药物)。
- 中重度或外用控制不佳者可考虑强推荐的系统靶向治疗(生物制剂或JAK抑制剂)。
- 避免系统糖皮质激素,慎用外用抗菌药与PUVA光疗。
局限性
- 分析基于制定时可得的最佳证据。
- 多数AD治疗随机对照试验持续时间短,限制长期疗效与安全性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric atopic dermatitis (AD) is a common, chronic inflammatory skin disorder that significantly impacts the quality of life of affected children and their families. Multiple therapies were approved to treat AD in children and adolescents since publication of the AAD's 2014 AD guidelines. OBJECTIVE: To provide evidence-based recommendations on the use of topical therapies, phototherapy, and systemic therapies for AD in children and adolescents. METHODS: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations. RESULTS: The workgroup developed 27 evidence-based recommendations on the medical management of pediatric AD. LIMITATIONS: This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of therapies for AD are of short duration limiting long-term efficacy and safety conclusions. CONCLUSIONS: We make strong recommendations for the use of moisturizers, topical calcineurin inhibitors, topical corticosteroids, crisaborole ointment, roflumilast cream, ruxolitinib cream, tapinarof cream, dupilumab, tralokinumab, lebrikizumab, nemolizumab with concomitant topical therapy, upadacitinib, abrocitinib, and baricitinib in the treatment of pediatric AD. We make conditional recommendations in favor of bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. We conditionally recommend against the use of topical antimicrobials, PUVA phototherapy, and strongly recommend against systemic corticosteroids.
引用
- Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2026. PMID: 41949508. doi:10.1016/j.jaad.2026.02.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。